Navigation Links
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
Date:5/17/2009

f Staphylococcus aureus in infected macrophages, (Poster P 1025). The final poster shows that NXL103 was active in vitro against both community-acquired and hospital-acquired strains of MRSA. The poster also showed that NXL103 was subject to a low spontaneous frequency of resistance (Poster P 1102).

It is Novexel's intention to seek partners for both the NXL104/ceftazidime combination and NXL103 in certain geographies.

All four posters will be available for download from Novexel's web site (http://www.novexel.com) shortly after the close of the ECCMID conference.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated US$17bn in 2008.[1]

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by Novexel's partner, Forest Laboratories (NYSE: '/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
2. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
3. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
4. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
5. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
6. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
9. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
10. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
11. Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
(Date:7/10/2014)... CAESAREA, Israel , July 10, 2014 /PRNewswire/ ... Dario™ Diabetes Management Solution, today announced the appointment ... an independent member of its Board of Directors. ... of legal and business experience to LabStyle as ... director, and legal and corporate governance expert. He ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) ... November 30, 2013, compared to sales of $2,202,000 for the ... again, this quarter has also shown growth over the preceding ... quarter of this fiscal year. Markets that experienced sales increases ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... WASHINGTON, Sept. 7, 2011 Team AFib™, a ... a series of initiatives designed to educate Americans ... stroke(1) during September,s National Atrial Fibrillation Awareness Month. ... awareness about AFib and stroke, Team AFib is ...
... 7, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced positive top-line results from a pilot clinical ... of XIAFLEX® (collagenase clostridium histolyticum) in adult Dupuytren,s ... profile following concurrent injection of two doses of ...
Cached Medicine Technology:Team AFib™ Unites Patient Advocacy Organizations to Elevate Understanding of Atrial Fibrillation and Stroke 2Team AFib™ Unites Patient Advocacy Organizations to Elevate Understanding of Atrial Fibrillation and Stroke 3Team AFib™ Unites Patient Advocacy Organizations to Elevate Understanding of Atrial Fibrillation and Stroke 4Team AFib™ Unites Patient Advocacy Organizations to Elevate Understanding of Atrial Fibrillation and Stroke 5Team AFib™ Unites Patient Advocacy Organizations to Elevate Understanding of Atrial Fibrillation and Stroke 6Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study 2Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study 3Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study 4
(Date:7/13/2014)... July 13, 2014 The report ... Molybdenum, Iron), Form (Chelated & Non Chelated), Application ... - Global Trends and Forecast to 2018” defines ... an analysis and forecasting of the global value ... the driving and restraining factors for the global ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 MarketsandMarkets ... Market [3D Modeling; 3D Scanning; 3D rendering; Layout ... and Analysis (2013 - 2018)”, which analyzes and ... in North America, Western Europe, Eastern Europe, Middle ... report also draws the competitive landscape of the ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are prone ... research presented today at the American Orthopaedic Society for ... marks the first of its kind investigating a genetic ... that occur after a head injury. , “We ... (GT)n genotype were four times more likely to have ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, MyDressCity.com, ... and women’s special occasion outfits, has released its new ... all the new products are available at discounted prices. ... 26, 2014. , In the company’s online shop, ... all of them are made with great materials. MyDressCity.com’s ...
(Date:7/13/2014)... decreased ability to identify odors might indicate the ... examinations of the eye could indicate the build-up ... the brain, according to the results of four ... International Conference 2014 (AAIC 2014) in Copenhagen. , ... to identify odors was significantly associated with loss ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... RESEARCH TRIANGLE PARK, N.C., May 27 Family,Health ... the,organization will introduce a number of new publications ... 27-31, 2008, at the,Omni Shoreham Hotel in Washington, ... on topics including the public health,impact of the ...
... New technology from Varian Medical Systems delivers faster image-guided,intensity-modulated radiotherapy (IMRT) ... ... healthy tissue, PLANO, Texas, May 27 Earlier this ... medical center in the United States to commence treating cancer,patients with ...
... called flavanols may be responsible for the benefit, study says ... about chocolate being good for your health is starting to ... a scientific division. , And a group of researchers, some ... Symbioscience, has just published a report showing that an enriched ...
... Christine Jacobs-Wagner has been designated an investigator of ... medical research organization that is one of the ... Associate Professor of Molecular, Cellular and Developmental Biology, ... hold the prestigious appointment. HHMI was founded to ...
... GOCE. The change of date is due to precautionary ... of a Russian Proton launcher. Now confirmed not to ... to date is scheduled for lift-off on 10 September ... date, the Gravity field and steady-state Ocean Circulation Explorer ...
... World No Tobacco Day, 31 May, the,International Union Against ... a comprehensive ban on all forms of,advertising, promotion and ... smoking before the age of 18. Almost one,fourth begin ... they first,try smoking, the more likely they are to ...
Cached Medicine News:Health News:Family Health International Featured at Global Health Council Conference 2Health News:Family Health International Featured at Global Health Council Conference 3Health News:Family Health International Featured at Global Health Council Conference 4Health News:Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology 2Health News:Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology 3Health News:Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology 4Health News:Enriched Cocoa Improves Blood Flow in Diabetics 2Health News:Enriched Cocoa Improves Blood Flow in Diabetics 3Health News:Jacobs-Wagner named Howard Hughes Investigator 2Health News:September launch for ESA's gravity mission GOCE 2Health News:September launch for ESA's gravity mission GOCE 3Health News:World No Tobacco Day: Global Organizations Join Forces To Break the Tobacco Marketing Net and Help Children Grow Up Smoke-Free 2
... Filter Units,Filter units with hydrophobic PTFE ... membrane are ideal for the sterilizing ... sterile containers, and for sterilizing or ... mm Millex filter units are available ...
... -4C. 5.5 Cubic Ft. ... light. Manual push button ... Two shelves. In-door shelves ... thermostat. Magnetic gasket. Hermetically ...
The incorporation of a reverse osmosis (RO) system and an ultrapure water system into a single stand-alone tower provides numerous benefits to the busy laboratory....
... L/min of Type I ultrapure water, , ... Plus System is designed to provide the ... pretreated by reverse osmosis, distillation or deionization. ... quality which exceeds Type I ASTM/CAP/NCCLS specifications.,The ...
Medicine Products: